J Vet Sci.  2015 Sep;16(3):333-340. 10.4142/jvs.2015.16.3.333.

Serum adipokine concentrations in dogs with diabetes mellitus: a pilot study

Affiliations
  • 1Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University, Cheongju 361-763, Korea. jhkang@chungbuk.ac.kr

Abstract

This study was conducted to determine whether serum adipokine concentrations differed between healthy dogs and dogs with diabetes mellitus (DM). To accomplish this, 19 dogs with newly diagnosed DM were compared to 20 otherwise healthy dogs. The serum concentrations of visfatin, leptin, IL-1beta, IL-6, IL-18, and TNF-alpha were significantly higher in diabetic dogs than in healthy dogs, whereas the serum adiponectin concentrations were lower in diabetic dogs. However, there were no significant differences in the IL-10 and resistin levels between groups. The serum leptin concentrations in diabetic dogs with and without concurrent disorders differed significantly. Treatment with insulin induced a significant decrease in IL-6 in diabetic dogs without concurrent disorders. These results show that the clinical diabetic state of dogs could modulate the circulating visfatin and adiponectin concentrations directly, while upregulation of leptin was probably a result of concurrent disorders rather than an effect of persistent hyperglycemia as a result of DM.

Keyword

adiponectin; canine; interleukin; leptin; visfatin

MeSH Terms

Adipokines/*blood
Animals
Case-Control Studies
Diabetes Mellitus, Type 2/*blood/etiology
Dogs
Female
Male
Pilot Projects
Prospective Studies
Adipokines

Figure

  • Fig. 1 Scatter plots of the serum leptin, visfatin, adiponectin, and resistin concentrations in healthy dogs (n = 20) and dogs with diabetes mellitus (n = 19). The horizontal bars indicate the median and range. *The median values were significantly (p < 0.05) different in healthy dogs and diabetic dogs (Mann-Whitney U test). DM: diabetes mellitus.

  • Fig. 2 Scatter plots of the serum leptin, visfatin, adiponectin, and resistin concentrations in healthy dogs (n = 20), diabetic dogs without concurrent diseases (n = 8), and diabetic dogs with concurrent diseases (n = 11). The horizontal bars indicate the median and range. *The median values were significantly (p < 0.05) different in healthy dogs and diabetic dogs (Mann-Whitney U test).


Reference

1. Alexiadou K, Kokkinos A, Liatis S, Perrea D, Katsilambros N, Tentolouris N. Differences in plasma apelin and visfatin levels between patients with type 1 diabetes mellitus and healthy subjects and response after acute hyperglycemia and insulin administration. Hormones (Athens). 2012; 11:444–450.
Article
2. Araya AV, Pavez V, Perez C, Gonzalez F, Columbo A, Aguirre A, Schiattino I, Aguillón JC. Ex vivo lipopolysaccharide (LPS)-induced TNF-α, IL-1β, IL-6 and PGE2 secretion in whole blood from Type 1 diabetes mellitus patients with or without aggressive periodontitis. Eur Cytokine Netw. 2003; 14:128–133.
3. Carrero JJ, Nakashima A, Qureshi AR, Lindholm B, Heimbürger O, Bárány P, Stenvinkel P. Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. Kidney Int. 2011; 79:749–756.
Article
4. Catchpole B, Ristic JM, Fleeman LM, Davison LJ. Canine diabetes mellitus: can old dogs teach us new tricks? Diabetologia. 2005; 48:1948–1956.
Article
5. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006; 91:295–299.
Article
6. Cho KD, Paek J, Kang JH, Chang D, Na KJ, Yang MP. Serum adipokine concentrations in dogs with naturally occurring pituitary-dependent hyperadrenocorticism. J Vet Intern Med. 2014; 28:429–436.
Article
7. Choi SH, Hong ES, Lim S. Clinical implications of adipocytokines and newly emerging metabolic factors with relation to insulin resistance and cardiovascular health. Front Endocrinol (Lausanne). 2013; 4:97.
Article
8. Dyck DJ, Heigenhauser GJ, Bruce CR. The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity. Acta Physiol (Oxf). 2006; 186:5–16.
Article
9. El-Mesallamy HO, Kassem DH, El-Demerdash E, Amin AI. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism. 2011; 60:63–70.
Article
10. DiMascio L, Voermans C, Uqoezwa M, Duncan A, Lu D, Wu J, Sankar U, Reya T. Identification of adiponectin as a novel hemopoietic stem cell growth factor. J Immunol. 2007; 178:3511–3520.
Article
11. Fall T, Hamlin HH, Hedhammar A, Kämpe O, Egenvall A. Diabetes mellitus in a population of 180,000 insured dogs: incidence, survival, and breed distribution. J Vet Intern Med. 2007; 21:1209–1216.
Article
12. Forsblom C, Thomas MC, Moran J, Saraheimo M, Thorn L, Wadén J, Gordin D, Frystyk J, Flyvbjerg A, Groop PH. FinnDiane Study Group. Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J Intern Med. 2011; 270:346–355.
Article
13. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005; 307:426–430.
Article
14. Guptill L, Glickman L, Glickman N. Time trends and risk factors for diabetes mellitus in dogs: analysis of veterinary medical data base records (1970-1999). Vet J. 2003; 165:240–247.
Article
15. Haider DG, Pleiner J, Francesconi M, Wiesinger GF, Müller M, Wolzt M. Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes. J Clin Endocrinol Metab. 2006; 91:4702–4704.
Article
16. Ishioka K, Hosoya K, Kitagawa H, Shibata H, Honjoh T, Kimura K, Saito M. Plasma leptin concentration in dogs: effects of body condition score, age, gender and breeds. Res Vet Sci. 2007; 82:11–15.
Article
17. Karpavicius A, Dambrauskas Z, Sileikis A, Vitkus D, Strupas K. Value of adipokines in predicting the severity of acute pancreatitis: comprehensive review. World J Gastroenterol. 2012; 18:6620–6627.
Article
18. Kitabchi AE, Stentz FB, Umpierrez GE. Diabetic ketoacidosis induces in vivo activation of human T-lymphocytes. Biochem Biophys Res Commun. 2004; 315:404–407.
Article
19. Lee JM, Kim SR, Yoo SJ, Hong OK, Son HS, Chang SA. The relationship between adipokines, metabolic parameters and insulin resistance in patients with metabolic syndrome and type 2 diabetes. J Int Med Res. 2009; 37:1803–1812.
Article
20. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009; 302:179–188.
Article
21. López-Bermejo A, Chico-Juliá B, Fernández-Balsells M, Recasens M, Esteve E, Casamitjana R, Ricart W, Fernández-Real JM. Serum visfatin increases with progressive β-cell deterioration. Diabetes. 2006; 55:2871–2875.
Article
22. Maggiore AD, Nelson RW, Dennis J, Johnson E, Kass PH. Efficacy of protamine zinc recombinant human insulin for controlling hyperglycemia in dogs with diabetes mellitus. J Vet Intern Med. 2012; 26:109–115.
Article
23. Malyszko J, Malyszko JS, Kozminski P, Pawlak K, Mysliwiec M. Adipokines, linking adipocytes and vascular function in hemodialyzed patients, may also be possibly related to CD146, a novel adhesion molecule. Clin Appl Thromb Hemost. 2008; 14:338–345.
Article
24. Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E, Dardeno TA, Kim SY, Hamnvik OPR, Koniaris A. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab. 2011; 301:E567–E584.
Article
25. Muse ED, Obici S, Bhanot S, Monia BP, McKay RA, Rajala MW, Scherer PE, Rossetti L. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest. 2004; 114:232–239.
Article
26. O'Neill S, Drobatz K, Satyaraj E, Hess R. Evaluation of cytokines and hormones in dogs before and after treatment of diabetic ketoacidosis and in uncomplicated diabetes mellitus. Vet Immunol Immunopathol. 2012; 148:276–283.
27. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997; 40:1286–1292.
Article
28. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med. 2008; 14:741–751.
Article
29. Radin MJ, Sharkey LC, Holycross BJ. Adipokines: a review of biological and analytical principles and an update in dogs, cats, and horses. Vet Clin Pathol. 2009; 38:136–156.
Article
30. Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, Imai S. Nampt/PBEF/Visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007; 6:363–375.
Article
31. Rucinsky R, Cook A, Haley S, Nelson R, Zoran DL, Poundstone M;. AAHA diabetes management guidelines. J Am Anim Hosp Assoc. 2010; 46:215–224.
32. Saraheimo M, Forsblom C, Thorn L, Wadén J, Rosengård-Bärlund M, Heikkilä O, Hietala K, Gordin D, Frystyk J, Flyvbjerg A, Groop PH. FinnDiane Study Group. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care. 2008; 31:1165–1169.
Article
33. Schäffler A, Schölmerich J, Salzberger B. Adipose tissue as an immunological organ: Toll-like receptors, C1q/TNFs and CTRPs. Trends Immunol. 2007; 28:393–399.
Article
34. Schwartz DR, Lazar MA. Human resistin: found in translation from mouse to man. Trends Endocrinol Metab. 2011; 22:259–265.
Article
35. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature. 1997; 389:610–614.
Article
36. Verkest KR, Bjornvad CR. Understanding adiponectin in dogs and cats: a work in progress. Vet J. 2012; 193:4–5.
Article
37. Verkest KR, Fleeman LM, Morton JM, Ishioka K, Rand JS. Compensation for obesity-induced insulin resistance in dogs: assessment of the effects of leptin, adiponectin, and glucagon-like peptide-1 using path analysis. Domest Anim Endocrinol. 2011; 41:24–34.
Article
38. Verkest KR, Rand JS, Fleeman LM, Morton JM, Richards AA, Rose FJ, Whitehead JP. Distinct adiponectin profiles might contribute to differences in susceptibility to type 2 diabetes in dogs and humans. Domest Anim Endocrinol. 2011; 41:67–73.
Article
39. Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer. 2007; 14:189–206.
Article
Full Text Links
  • JVS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr